Muscle loss linked to immunotherapy response in lung cancer

NCT ID NCT07192926

Completed Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looked at 115 adults with advanced non-small cell lung cancer to see if muscle loss (sarcopenia) and a blood-based score called CTI affect how well immunotherapy works. Researchers reviewed medical records to measure muscle on CT scans and calculate CTI from routine blood tests. The goal is to find simple markers that could help doctors predict which patients will benefit most from treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 neoplasm non-small cell lung carcinoma Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON-SMALL CELL LUNG CANCER NEOPLASM

Contacts and locations

Locations

Etlik City Hospital Medical Oncology Department

Ankara, Yenimahalle, 06270, Turkey (Türkiye)
Etlik City Hospital Radiology Department

Ankara, Yenimahalle, 06270, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.